Edison Pharmaceuticals Lands Series E

Mountain View-based Edison Pharmaceuticals, a developer of treatments for inherited mitochondrial diseases and other rare and neglected diseases, said today that it has raised a Series E preferred financing round. Financial details of the funding, and source of funds, were not disclosed. The firm said the funding will go towards US and European trials of its clinical candidates. A recent regulatory filing from the firm indicates the company recently raised around $4.0M in funding. More information »